BLOOD BANK TESTING
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FA2396 USAF AFMC AFRL PZL AFRL PZLE
Contract Value
Not provided
Codes & Classification
Solicitation Number
SS-AFRL-PZLEQ-2026-0005
NAICS
325413 - In-Vitro Diagnostic Substance Manufacturing
Classification Code
6550
Additional Details
Documents2
The Department of the Air Force, through the Air Force Research Laboratory (AFRL) at Wright Patterson Air Force Base in Ohio, has issued a Sources Sought notice under procurement identifier SS-AFRL-PZLEQ-2026-0005 for BLOOD BANK TESTING. This notice seeks to identify potential sources capable of providing products or services related to in-vitro diagnostic substance manufacturing, as classified under NAICS code 325413 (2022 version), with a corresponding Product Service Code of 6550.
The primary objective of this procurement is to support blood bank testing requirements at Wright Patterson AFB. While the specific scope and deliverables are detailed in the attached documents (not included here), the focus is on acquiring in-vitro diagnostic substances or related testing capabilities essential for blood bank operations. The intended outcome is to ensure the availability of reliable, high-quality diagnostic solutions that meet the operational needs of the Air Force’s medical and research missions at this location.
The contracting activity is managed by the AFRL PZL office (FA2396 USAF AFMC AFRL PZL AFRL PZLE), a federal entity within the Department of Defense. The place of performance is exclusively at Wright Patterson AFB, Ohio, United States.
This notice is a Sources Sought, indicating that the government is conducting market research to determine the availability and capability of qualified vendors prior to issuing a formal solicitation. There is no indication of set-aside requirements or special considerations at this stage; all interested parties are encouraged to respond. Contractors should review the attached documents for further technical and performance requirements.
Interested vendors are invited to submit their capabilities and relevant information by the response deadline of January 28, 2026, at 20:01. The notice remains active as of its posting date, January 21, 2026. For further information or to submit responses, contractors may contact the primary point of contact, Mike Hornberger ([email protected], 937-713-0549), or the secondary contact, Jessica Briggs ([email protected]).
Additional details, including attachments, can be accessed via the official SAM.gov opportunity page at: https://sam.gov/opp/a3759166dfdc4f198a52c8682b781b7c/view.
This opportunity is particularly relevant for organizations with expertise in manufacturing or supplying in-vitro diagnostic substances for blood bank applications, and those with experience supporting federal or military medical operations.